ExThera Medical

ExThera Medical Corporation is developing revolutionary medical devices that address unmet clinical needs for the treatment of bloodstream infections and pathogen-reduction in blood banking. The company was formed in 2008 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB of Stockholm in 2008 and is currently conducting clinical studies of its first product, the Seraph® Microbind® Affinity Blood Filter. The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, but also intends to develop a device that prophylactically safeguards banked human blood. Located in the San Francisco Bay area, the company is led by an experienced and seasoned management team, has a significant number of well-protected patents and a growing body of data from both company and independent laboratory conducted studies being used to advance Seraph toward clinical approval.